Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01853280 · ClinicalTrials.gov registry record · Phase 2
L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT01853280: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT01853280 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 47 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01853280, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
This pilot study seeks to evaluate initial evidence for the effect of L-methylfolate supplementation to OROS-Methylphenidate pharmacotherapy on ADHD symptoms and associated features in adults with ADHD, as well as tolerability of this supplementation. The investigators will conduct a 12-week double-blind randomized placebo-controlled trial with L-methylfolate supplementing open-label OROS-Methylphenidate (OROS-MPH). The investigators propose to examine 40 adult (ages 18-55) subjects satisfying the DSM-IV diagnostic criteria for ADHD.
Interventions
- DRUG Placebo
- DRUG OROS-Methylphenidate
- DRUG L-methylfolate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2014-05 |
| Est. Completion | 2017-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01853280
The ClinicalTrials.gov registry entry for NCT01853280 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01853280 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01853280 about?
NCT01853280 is a clinical study titled "L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults". This pilot study seeks to evaluate initial evidence for the effect of L-methylfolate supplementation to OROS-Methylphenidate pharmacotherapy on ADHD symptoms and associated features in adults with ADHD, as well as tolerability of this supplementation. The investigators will conduct a 12-week double-...
What is the current status of trial NCT01853280?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2014-05. Estimated completion is 2017-09.
What interventions are being tested in trial NCT01853280?
The interventions under investigation include: Placebo (DRUG), OROS-Methylphenidate (DRUG), L-methylfolate (DRUG).
Who is sponsoring clinical trial NCT01853280?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.